Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01643928 · ClinicalTrials.gov registry record · NA
Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)
A NA study, sponsored by Pfizer.
- Completed
- Registry status
- NA
- Development phase
- 185
- Enrollment target
NCT01643928 is a NA study that has completed, run by Pfizer. The registered enrollment target is 185 participants.
The verdict
NCT01643928, a NA study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- NA
- Development phase
- 185 participants
- Enrollment target
Study Summary
This extension study will evaluate the safety (including immunogenicity) of treatment with rituximab-Pfizer, as well as the safety and immunogenicity after transitioning from rituximab-US or rituximab-EU to rituximab-Pfizer. This study will provide continued treatment access to subjects with active rheumatoid arthritis who have participated for at least 16 weeks in other studies in the rituximab Pfizer program.
Interventions
- BIOLOGICAL Rituximab-Pfizer (PF-05280586) x 3 courses
- BIOLOGICAL Rituximab-EU+ Rituximab-Pfizer x 2 Courses
- BIOLOGICAL Rituximab-US + Rituximab-Pfizer x 2 Courses
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2012-08-16 |
| Est. Completion | 2016-03-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01643928
The ClinicalTrials.gov registry entry for NCT01643928 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rituximab-Pfizer (PF-05280586) x 3 courses is the first listed.
NCT01643928 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01643928 about?
NCT01643928 is a clinical study titled "Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)". This extension study will evaluate the safety (including immunogenicity) of treatment with rituximab-Pfizer, as well as the safety and immunogenicity after transitioning from rituximab-US or rituximab-EU to rituximab-Pfizer. This study will provide continued treatment access to subjects with active ...
What is the current status of trial NCT01643928?
This trial is currently completed. It is a NA study. The enrollment target is 185 participants. The study started on 2012-08-16. Estimated completion is 2016-03-14.
What interventions are being tested in trial NCT01643928?
The interventions under investigation include: Rituximab-Pfizer (PF-05280586) x 3 courses (BIOLOGICAL), Rituximab-EU+ Rituximab-Pfizer x 2 Courses (BIOLOGICAL), Rituximab-US + Rituximab-Pfizer x 2 Courses (BIOLOGICAL).
Who is sponsoring clinical trial NCT01643928?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.